Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Mixed cancer vaccines, CHP-HER2 protein and CHP-NY-ESO-1 protein, are to be studied to evaluate the safety and immune responses in patients who are positive either or both antigens. Nine patients will be enrolled, who are refractory to standard therapies for cancer or at high risk to relapse. CHP-HER2 and CHP-NY-ESO-1 are subcutaneously given on bimonthly basis, together with OK-432(Picibanil) as an immunoadjuvant. Six doses will be given. Toxicity profiles will be monitored, and antigen specific humoral anad T cell responses will be described.
Condition or disease
Esophageal CancerLung CancerStomach CancerBreast CancerOvarian Cancer
Safety and Immunogenicity of Cholesterol-Bearing Hydrophobized Pullulan HER2 Protein 146 (CHP-HER2) and NY-ESO-1 Protein (CHP-NY-ESO-1) in Combination With OK-432 in HER2- and/or NY-ESO-1-Expressing Cancers
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histological confirmation of cancer.
HER2 expression in tumor cells scored as 1+ or more which should be confirmed by IHC using at least two antibodies (archived issue; see Appendix 1 and Reference 1 for methodology).
or NY-ESO-1 expression by reverse transcriptase and polymerase chain reaction (RT-PCR) analysis (Appendix 2), preferably, or immunohistochemistry
are at high risk of recurrence, more than 25% of probability, after complete resection or even after post-operative adjuvant treatment, and effective adjuvant therapy is not available or refused; or
have metastatic disease, and treatment has failed, or in the situation where effective therapy is not available, or has been refused.
Complete recovery from surgery (at least 4 weeks).
Laboratory values within the following limits:
Hemoglobin 9.0 g/dL or more, or 10.0 g/dL or more if <50 kg Neutrophil count >1.5 x 109/L Lymphocyte count >0.5 x 109/L Platelet count >100 x 109/L Serum creatinine ≤ 1.8 mg/dL Serum bilirubin ≤ 2 mg/dL
Performance status > 70 (Karnofsky Scale) and life expectancy >3 months.
Age 18 years or more.
Clinically significant heart disease (NYHA Class III or IV).
Cardiac dysfunction; less than 50% of ejection fraction by echocardiogram.
Other serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders.
Previous bone marrow or stem cell transplant.
Metastatic disease to the central nervous system, unless treated and stable.
known HIV antibody positivity.
Anaphylactic reaction to previous vaccination.
Hypersensitivity to penicillin
Chemotherapy, any type of radiation therapy, or immunotherapy within 4 weeks before study entry (6 weeks for nitrosoureas).
Concomitant treatment with steroids. Topical or inhalational steroids are permitted.
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.
Pregnancy or nursing .
Refusal, by women of childbearing potential, to use medically acceptable means of contraception.
Mental impairment that may compromise the ability to give informed consent.
Lack of availability for immunological and clinical follow-up assessment.